Q3 EPS Estimate for Generate Biomedicines Lowered by Analyst

Key Points

• HC Wainwright lowered its Q3 2026 EPS estimate for Generate Biomedicines to a loss of $0.55 per share from $0.52, while maintaining a Buy rating and $25 price target.
• Generate Biomedicines reported a quarterly loss of $0.52 per share, missing the $0.48 consensus estimate, with revenue of $6.31 million.
• Analyst sentiment remains broadly positive, with six Buy ratings and one Hold rating producing a Moderate Buy consensus and an average price target of $25.40; shares opened at $14.72 after rising 2.6%.

Generate Biomedicines Inc (NASDAQ:GENB - Free Report) - HC Wainwright lowered their Q3 2026 earnings per share (EPS) estimates for shares of Generate Biomedicines in a research report issued on Friday, August 7th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($0.55) for the quarter, down from their previous forecast of ($0.52). HC Wainwright has a "Buy" rating and a $25.00 price target on the stock. The consensus estimate for Generate Biomedicines' current full-year earnings is ($2.29) per share. HC Wainwright also issued estimates for Generate Biomedicines' FY2026 earnings at ($2.16) EPS, Q1 2027 earnings at ($0.58) EPS, Q2 2027 earnings at ($0.51) EPS and Q4 2027 earnings at ($0.50) EPS.

Generate Biomedicines (NASDAQ:GENB - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The business had revenue of $6.31 million during the quarter.

Several other research analysts have also commented on GENB. Wall Street Zen lowered shares of Generate Biomedicines from a "hold" rating to a "sell" rating in a report on Saturday. Morgan Stanley boosted their price target on Generate Biomedicines from $20.00 to $22.00 and gave the company an "overweight" rating in a research note on Thursday, May 14th. Six equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, Generate Biomedicines has a consensus rating of "Moderate Buy" and a consensus price target of $25.40.

Generate Biomedicines Stock Up 2.6%

NASDAQ GENB opened at $14.72 on Tuesday. Generate Biomedicines has a 1-year low of $11.00 and a 1-year high of $18.18. The firm has a market cap of $1.89 billion and a price-to-earnings ratio of -13.76. The company has a 50-day moving average price of $14.48.

Institutional Investors Weigh In On Generate Biomedicines

A hedge fund recently bought a new stake in Generate Biomedicines stock. Bank of New York Mellon Corp acquired a new stake in Generate Biomedicines Inc (NASDAQ:GENB - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 57,326 shares of the company's stock, valued at approximately $967,000.

About Generate Biomedicines

Generate Biomedicines, Inc NASDAQ: GENB is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source